Analysis of Prognostic Significance of Merkel Cell Polyomavirus in Chronic Lymphocytic Leukemia

Investor logo
Investor logo
Investor logo

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

TRIZULJAK Jakub SROVNAL Josef PLEVOVÁ Karla BRYCHTOVÁ Yvona SEMERÁD Lukáš BAKEŠOVÁ Denisa LÉTALOVÁ Eva BENEDÍKOVÁ Andrea MAYER Jiří HAJDÚCH Marian POSPÍŠILOVÁ Šárka DOUBEK Michael

Year of publication 2015
Type Article in Periodical
Magazine / Source Clinical Lymphoma Myeloma & Leukemia
MU Faculty or unit

Faculty of Medicine

Citation
Web http://ac.els-cdn.com/S2152265015000324/1-s2.0-S2152265015000324-main.pdf?_tid=35610b90-3b65-11e5-9c14-00000aacb35d&acdnat=1438774338_b787fb4ae3f955d7a6bbe61376e2b860
Doi http://dx.doi.org/10.1016/j.clml.2015.02.003
Field Oncology and hematology
Keywords Chronic lymphocytic leukemia; Merkel cell polyomavirus; Overall survival; Polymerase chain reaction; Prognostic factors
Description Merkel cell polyomavirus (MCPyV) has been found to be associated with chronic lymphocytic leukemia (CLL). We evaluated its prognostic significance in CLL. MCPyV occurrence seems to be a relatively rare event during the course of CLL. MCPyV is also unlikely to influence the outcome of CLL patients. Background: Merkel cell polyomavirus (MCPyV), a ubiquitous DNA tumor virus, has been found to be associated with Merkel cell carcinoma and chronic lymphocytic leukemia (CLL). Previous studies have reported conflicting results on the frequency and potential pathogenetic role of MCPyV in CLL. The aim of this study was to evaluate MCPyV's association with CLL and its prognostic significance. Patients and Methods: Between 2006 and 2013, DNA samples obtained from CLL patients (n = 119) before treatment were tested for MCPyV using quantitative real-time polymerase chain reaction analysis and verified by gel electrophoresis. Only samples testing positive by both methods were considered valid. Results: We found that 13 (11%) of 119 CLL cases were positive for MCPyV. Between the groups of MCPyV-positive and -negative patients, there was no significant difference in the sex, age, cytogenetics, presence of p53 defect, or immunoglobulin heavy chain (IGHV) mutational status. In the subset of MCPyV-negative patients, advanced Rai stage (III to IV) was found more frequently, and therapy was initiated more often. There was no difference in overall response rate, median progression-free survival, and overall survival between both groups. We did not observe any new positivity after treatment in initially MCPyV-negative patients. Conclusion: This study provides the first analysis of the prognostic role of MCPyV in CLL. MCPyV occurrence seems to be a relatively rare event during the course of CLL. MCPyV is also unlikely to influence the outcome of CLL patients.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.